Astellas Pharma Inc. Site Map
 
Home > Therapeutic Areas > R&D > Agensys, Inc.
   
Agensys, Inc.

Agensys, Inc., an affiliate of Astellas Pharma Inc., specializes in therapeutic antibody research and development in cancer. Agensys is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers.

The MAb product pipeline is being generated to Agensys' diverse portfolio of proprietary, clinically relevant cancer targets that encompass 14 types of solid tumors. Agensys' target portfolio and related products are protected by 119 issued/33 allowed patents and over 300 applications. The Company has full capabilities to generate, develop and manufacture antibody products.

Agensys is progressing a pipeline of both naked and antibody-drug conjugated (ADC) therapeutic antibodies, directed at a variety of cancer indications, including those of the prostate, kidney, pancreas, ovary, bladder, lung, colon, breast and skin. ADC products are based on toxin platform technologies developed by Seattle Genetics.

Today, Agensys has a rich pipeline that includes four monoclonal antibody products in clinical trials: (1) AGS-1C4D4, directed to Prostate Stem Cell Antigen (PSCA), a novel target for prostate, pancreatic, and bladder cancers; (2) AGS-5ME, Agensys' first ADC, directed to AGS-5, a novel target in multiple epithelial tumors, co-developed with Seattle Genetics; (3) AGS-16M8F, an ADC developed for the treatment of metastatic renal cancer; and (4) AGS-22M6E, an ADC developed for multiple solid tumors to include breast, bladder, lung, and pancreatic cancers. Agensys' pre-clinical pipeline encompasses over 10 different MAb programs.

Agensys in January 2011 broke ground on a new 160,000-square-foot, state-of-the-art facility, which will help fulfill Astellas' mission of developing innovative pharmaceuticals for cancer patients with still unmet medical needs. When completed in early 2013, the campus will feature a pedestrian pathway, public café and a public sculpture garden featuring art by local artists that will change annually.

"The research and development facility that is to be built on these grounds will symbolize the promise of better days for cancer patients and their families around the globe," said Agensys President and CEO Dr. Sef Kurstjens.

Agensys began operations in Santa Monica in 1997, founded by oncologists at UCLA. In 2007, Astellas Pharma Inc. acquired Agensys with the plan to make it the center of the company's antibody product discovery and development operations.

   
 
Copyright © 2005 - 2009 Astellas Pharma US, Inc. Site Map  Privacy Policy  Legal Disclaimer  Contact Us